Related by context. All words. (Click for frequent words.) 70 stage IIIb IV 66 unresectable Stage III 66 HRPC ovarian cancer 64 metastatic pancreatic 64 evaluating picoplatin 64 squamous non 64 intravenous RSD# 63 resistant hormone refractory 63 EGFR mutation positive 63 refractory metastatic 62 recurrent NSCLC 62 unresectable locally advanced 62 CYT# potent vascular disrupting 62 stage IIIB IV 62 metastatic colorectal 62 Stage IIIB IV 62 Charles Dullin School 62 de novo kidney transplant 61 advanced hepatocellular carcinoma 61 Peginterferon alfa 2b 61 refractory indolent non 61 Folfox 60 metastatic bladder 60 tumors GIST 60 unresectable stage 60 stage IIIb 59 refractory NSCLC 59 older NSAID diclofenac 59 metastatic HER2 negative 59 treatment naïve genotype 59 dasatinib Sprycel 59 recurrent metastatic 59 metastatic colorectal carcinoma 59 nonsquamous histology 59 Stage IIIb 59 HER2 positive metastatic breast 59 dasatinib Sprycel ® 59 sorafenib Nexavar ® 59 relapsed refractory multiple myeloma 59 mRCC 59 nonmetastatic 58 comparing XIENCE V 58 metastatic CRPC 58 Aflibercept 58 metastatic GIST 58 regorafenib 58 cell carcinoma RCC 58 pancreatic colorectal 58 gemcitabine carboplatin 58 minimally symptomatic 58 sorafenib tablets 58 stage IIIB 58 recurrent glioblastoma multiforme 58 metastatic hormone refractory 58 medically inoperable 58 metastatic renal cell 58 advanced unresectable 58 biliary tract cancer 58 ACTEMRA TM 57 refractory colorectal cancer 57 metastatic gastric 57 trastuzumab Herceptin R 57 EQUIP OB 57 5 FU leucovorin 57 FOLFOX regimen 57 aflibercept VEGF Trap 57 completely resected 57 metastatic medullary thyroid 57 squamous histology 57 advanced metastatic renal 57 REVIVE Diabetes 57 Adjuvant chemotherapy 57 TTF Therapy 57 carboplatin paclitaxel 57 leukemia APL 57 refractory chronic lymphocytic 57 KRAS mutations occur 56 refractory AML 56 assessing T DM1 56 squamous cell histology 56 HBeAg negative 56 chemotherapy cisplatin 56 FOLFOX6 56 non myeloid malignancies 56 AVASTIN 56 HGS ETR1 mapatumumab 56 opioid induced constipation OIC 56 ZACTIMA 56 vinca alkaloids 56 anthracycline taxane 56 castrate resistant prostate cancer 56 doublet chemotherapy 56 advanced epithelial ovarian 56 heavily pretreated 56 CONQUER OB 56 colorectal ovarian 56 unresectable recurrent 56 nucleoside naive 56 Kit CD# positive 56 denosumab oncology clinical trials 56 refractory multiple myeloma 56 Ozarelix 56 LHRH receptor positive 56 metastatic castrate resistant 56 EGFR TKI 56 visiting HiltonHHonors.com 56 plus gemcitabine 55 KRAS mutant tumors 55 imatinib Gleevec ® 55 BRCA deficient 55 metastatic renal cell carcinoma 55 differentiated thyroid 55 haematologic malignancies 55 prostate cancer HRPC 55 refractory metastatic colorectal cancer 55 recurrent GBM 55 ABSORB clinical 55 Recurrent Glioblastoma 55 carcinoma HCC 55 non squamous 55 Glioblastoma Multiforme 55 Xeloda capecitabine 55 Motesanib 55 relapsed CLL 55 erlotinib Tarceva ® 55 CHAMPION PCI 55 chronic myeloid 55 metastatic carcinoma 55 IV malignant melanoma 55 TTR amyloidosis 55 phase IIb study 55 non resectable 55 MAGE A3 ASCI 55 Surgical resection 55 EGFR expressing 55 histologically confirmed 55 paclitaxel carboplatin 55 evaluating tivozanib 55 5-FU/LV 55 anthracycline containing 55 ovarian breast 54 peritoneal carcinomatosis 54 docetaxel Taxotere R 54 KRAS wild 54 capecitabine Xeloda 54 Acute Myelogenous Leukemia AML 54 NMIBC 54 Ixempra 54 IV metastatic melanoma 54 diagnosed Ph + 54 Study ARIC 54 treatment naive genotype 54 colorectal lung 54 YONDELIS 54 receptor tyrosine kinase inhibitor 54 Metastatic Colorectal Cancer 54 relapsed leukemia 54 advanced NSCLC 54 ErbB2 positive 54 Fludara ® 54 Annamycin 54 castrate resistant 54 IV melanoma 54 recurrent squamous cell carcinoma 54 recurrent malignant glioma 54 mCRC patients 54 CLL SLL 54 colon esophageal 54 nonsmall cell lung cancer 54 investigational immunotherapy 54 Pemetrexed 54 pegylated liposomal doxorubicin 54 AIR CF1 54 metastatic HER2 positive 54 forodesine 54 diagnosed GBM 54 systemic ALCL 54 Depressed bipolar 54 refractory CLL 54 sorafenib Nexavar 54 hepatocellular cancer 53 imetelstat GRN#L 53 monoclonal antibody conjugated 53 stage IIIA 53 unresectable 53 Irinotecan 53 Evoltra ® 53 leukemia AML 53 metastatic kidney 53 cancer mCRC 53 gemcitabine chemotherapy 53 Amrubicin 53 metastatic malignant 53 taxane chemotherapy 53 FOLFIRI 53 gastrointestinal stromal tumor GIST 53 BRIM2 53 recurrent colorectal cancer 53 multi kinase inhibitor 53 metastatic CRC 53 clinically localized prostate 53 protease inhibitor PI 53 gemcitabine Gemzar 53 metastatic HRPC 53 bladder ovarian 53 refractory chronic myeloid 53 Hepatocellular Carcinoma HCC 53 refractory CTCL 53 Alessandro Riva 53 metastatic colorectal cancer 53 wide receiver Kenbrell Thompkins 53 Cutaneous T 53 underwent liver transplantation 53 familial amyloidotic polyneuropathy FAP 53 HER2 negative 53 non squamous NSCLC 53 ovarian pancreatic 53 Mantle Cell Lymphoma 53 Chronic lymphocytic leukemia 53 PROSTVAC ® 53 Renal Cell Carcinoma RCC 52 vinca alkaloid 52 Tarceva TM 52 gefitinib Iressa 52 FLT3 mutations 52 Xelox 52 atypical Hemolytic Uremic Syndrome 52 VESTASYNC II trial 52 Al Hanay 52 metastatic castration resistant 52 registrational trial 52 prescribed CRESTOR 52 taxane therapy 52 EGFR expressing mCRC 52 PSMA ADC 52 fallopian tube carcinoma 52 IgG1 monoclonal antibody 52 interferon ribavirin 52 relapsed multiple myeloma 52 locoregional recurrence 52 Cytoxan 52 lung cancer NSCLC 52 BR.# 52 advanced adenomas 52 paclitaxel Taxol ® 52 sunitinib malate 52 COU AA 52 dose escalation phase 52 sunitinib Sutent 52 acyclovir Lauriad R 52 nonsquamous 52 fluoropyrimidine 52 hepatitis C HCV 52 IIIA NSCLC 52 Nexavar sorafenib 52 University http:/www.capella.edu 52 pancreatic prostate 52 leukemia CLL 52 malignant pleural mesothelioma 52 phase Ib 52 standard chemotherapy regimen 52 HRPC 52 Phase Ib II 52 glioblastoma multiforme GBM 52 pertuzumab 52 acute leukemias 52 oral sapacitabine 52 Vicinium TM 52 diagnosed glioblastoma multiforme 52 cisplatin chemotherapy 52 HER2 + 51 lymphoma CTCL 51 breast carcinomas 51 NSCLC 51 samalizumab 51 oral ridaforolimus 51 mapatumumab 51 superficial bladder cancer 51 platinum refractory 51 pancreatic carcinoma 51 antibody MAb 51 achieved sustained virological 51 alvespimycin 51 breast pancreatic 51 indolent NHL 51 Bezielle 51 lung pancreatic 51 symptomatic BPH 51 resectable 51 Quinamed 51 pain palliation 51 PNP inhibitor 51 lenalidomide Revlimid R 51 Metastatic breast cancer 51 histone deacetylase HDAC inhibitor 51 heavily pretreated patients 51 pegylated interferon alpha 51 Renal cell carcinoma 51 limiting generalizability 51 Aplidin 51 ABSORB trial 51 metastatic liver 51 unresectable liver cancer 51 metastatic relapsed 51 IV NSCLC 51 Nexavar tablets 51 lung malignant melanoma 51 refractory acute myeloid 51 controlled dose escalation 51 FOLFOX4 51 immunotherapeutic agent 51 small lymphocytic lymphoma 51 randomized #:#:# 51 pancreatic adenocarcinoma 51 Lung transplantation 51 remission induction 51 #mg ATC 51 follicular lymphoma FL 51 HER2 positive cancers 51 lumiliximab 51 recurrent glioblastoma 51 ovarian carcinoma 51 Virulizin ® 50 radiolabeled TM# 50 cisplatin resistant 50 Axitinib 50 medullary thyroid cancer 50 imatinib Gleevec 50 cutaneous T 50 Callisto initiated 50 ELOXATIN 50 Gemzar ® 50 KRAS mutant 50 Troxatyl 50 cytotoxic therapy 50 Doxil ® 50 recurrent glioblastoma multiforme GBM 50 cholangiocarcinoma 50 receiving TEMODAR 50 soft tissue sarcomas 50 relapsed SCLC 50 RESIST studies 50 hormone refractory prostate cancer 50 Erbitux cetuximab 50 histologies 50 antiretroviral naive 50 papillary renal cell carcinoma 50 prostate carcinoma 50 Paraplatin ® carboplatin 50 metastatic malignant melanoma 50 Herceptin trastuzumab 50 Medullary thyroid cancer 50 Fludara 50 bevacizumab Avastin ® 50 Apaziquone 50 refractory ovarian cancer 50 Chronic Lymphocytic Leukemia 50 BRAF inhibitor 50 cystic fibrosis bronchiectasis 50 myelofibrosis polycythemia vera 50 cytokine refractory 50 subependymal giant cell 50 lung colorectal 50 operable breast cancer 50 docetaxel Taxotere ® 50 Torisel 50 Allovectin 7 50 temsirolimus 50 Cloretazine 50 TEMODAL 50 APEX PD 50 EDUCATION Attended 50 OPT CHF 50 untreated CLL 50 docetaxel chemotherapy 50 underwent percutaneous coronary 50 mCRC 50 resistant ovarian cancer 50 ThermoDox R 50 prior chemotherapy regimens 50 CANCIDAS 50 AVID elective 49 Cell Lung Cancer 49 receiving antiretroviral therapy 49 biliary cancer 49 huN# DM1 49 neoadjuvant treatment 49 Romidepsin 49 follicular non 49 metastatic breast 49 metastatic squamous cell carcinoma 49 Genasense ® 49 basal cell carcinoma BCC 49 HGS ETR1 49 enzastaurin 49 MAGE A3 49 SIR Spheres 49 trastuzumab Herceptin ® 49 Vandetanib 49 refractory PTCL 49 chlorambucil 49 pancreatic gastric 49 thalidomide Thalomid 49 Cloretazine ® 49 cediranib 49 trastuzumab DM1 49 cutaneous melanoma 49 palliative radiotherapy 49 pan HDAC inhibitor 49 diagnosed glioblastoma 49 dose dose escalation 49 tumor xenograft models 49 NYHA Class II 49 TechLINKS Exchange contact tlx@techlinks.net 49 nonmelanoma skin cancers 49 cell lymphoma CTCL 49 IMPACT DCM trial 49 irinotecan chemotherapy 49 undergone splenectomy 49 axitinib 49 pancreatic NET 49 Insegia 49 blinded placebo controlled 49 Acute Myeloid Leukemia AML 49 undergoing coronary angiography 49 peritoneal cancer 49 blinded randomized placebo controlled 49 dacarbazine chemotherapy 49 locoregional 49 luteinizing hormone releasing 49 eribulin mesylate 49 HER2 positive 49 cabazitaxel 49 panitumumab Vectibix 49 cell lung cancer 49 Pegasys ® 49 anaplastic thyroid carcinoma 49 BRIM3 49 nab paclitaxel 49 LUX Lung 49 RRMS patients 49 underwent CABG 49 olaparib 49 IPF CAPACITY 49 colorectal pancreatic 49 BCIRG 49 AEG# 49 TYSABRI therapy 49 alkylating agent 49 docetaxel Taxotere 49 bendamustine 49 ovarian lung 49 Pirfenidone 49 gastrointestinal stromal tumors GIST 49 IRESSA 49 OvaRex ® MAb 48 IL# PE#QQR 48 colorectal liver metastases 48 Cimzia TM 48 metastatic RCC 48 untreated de novo 48 dacarbazine 48 non metastatic osteosarcoma 48 PANVAC VF 48 liposomal amphotericin B 48 Phase Ib clinical trials 48 relapsed refractory 48 chemoradiotherapy 48 mycophenolate mofetil 48 seminoma 48 Phase #b/#a clinical 48 gastrointestinal stromal tumors 48 Gleevec resistant 48 HNSCC 48 Afatinib 48 Swedish Mammography Cohort 48 mutated KRAS gene 48 Gemcitabine 48 cutaneous T cell 48 chemotherapeutic regimen 48 castration resistant prostate cancer 48 untreated AML 48 colorectal breast 48 Epratuzumab 48 CR# vcMMAE 48 leukemia ALL 48 Seliciclib 48 ELACYT 48 Allovectin 7 ® 48 randomized controlled multicenter 48 lintuzumab 48 Selective Internal 48 brain metastases 48 Jevtana 48 neratinib 48 talabostat 48 fasting triglyceride levels 48 Metastatic 48 phase IIb trial 48 Alemtuzumab 48 metastatic pancreatic cancer 48 CHOP chemotherapy 48 prostate cancer CRPC 48 XELOX 48 IMA# 48 diagnosed multiple myeloma 48 Follicular lymphoma 48 radiofrequency ablation RFA 48 Taxotere ® 48 undetectable HBV DNA 48 dosing cohort 48 ToGA 48 novel histone deacetylase 48 nasopharyngeal cancer 48 mutated KRAS 48 Xanafide 48 radiation sensitizer 48 neoadjuvant chemotherapy 48 gastric cancers 48 refractory prostate cancer 48 elacytarabine 48 Brain metastases 48 squamous cell cancer 48 biologic therapy 48 FOLFOX chemotherapy 48 squamous cell lung cancer 47 adecatumumab 47 systemic fungal infections 47 epithelial tumors 47 ixabepilone 47 iniparib 47 hormone receptor positive 47 phase IIb clinical 47 androgen independent 47 trastuzumab DM1 T DM1 47 Gefitinib 47 nasopharyngeal carcinoma 47 grade cervical intraepithelial 47 micafungin 47 controlled multicenter 47 EFAPROXYN 47 VFEND 47 Cetuximab Erbitux 47 microtubule inhibitor 47 MPS IVA 47 BRCA mutation carriers 47 mycosis fungoides 47 OncoVEX GM CSF 47 relapsed ovarian cancer 47 EDUCATION BA 47 runic setup signifies 47 malignant polyps 47 cilengitide 47 refractory Hodgkin lymphoma 47 Ceflatonin 47 neuroendocrine cancers 47 Velcade bortezomib 47 Glioblastoma Multiforme GBM 47 EOquin TM 47 squamous cell carcinoma SCC 47 vismodegib 47 carcinoid tumors 47 Associate Degree Nursing ADN 47 HIV uninfected 47 liposomal doxorubicin 47 unduplicated headcount 47 IMC #B 47 pancreatic ovarian 47 SJIA 47 Rituxan rituximab 47 haematological malignancies 47 anti EGFR antibody 47 trabectedin 47 pemetrexed 47 refractory APL 47 Tamibarotene 47 lung carcinomas 47 bladder cancers 47 metastatic colon cancer 46 docetaxel 46 Canvaxin 46 Hycamtin 46 IRX 2 46 HGS# 46 flush apalooza 46 progressive MS SPMS 46 imatinib resistant 46 xenograft models 46 neoadjuvant 46 LE DT 46 cytotoxic chemotherapy 46 cetuximab Erbitux ® 46 imetelstat 46 interferon alfa 46 epithelial ovarian cancer 46 gemcitabine 46 Drury Evangel 46 gastrointestinal stromal tumor 46 Merck KGaA Erbitux 46 FOLOTYN ® 46 adjuvant radiation 46 skeletal metastases 46 non alcoholic steatohepatitis 46 calcium phosphate binder 46 LBH# 46 proteasome inhibitor 46 Taxotere R 46 VNP#M 46 federally funded TRIO 46 invasive candidiasis 46 treatment naļve 46 abiraterone acetate 46 lymphocytic leukemia 46 DCVax R Brain 46 sorafenib 46 cetuximab Erbitux 46 FOLFOX 46 adenocarcinomas 46 T#I [002] 46 metastatic lung cancer 46 renal cell carcinoma 46 diagnosed Glioblastoma multiforme 46 gefitinib 46 candidemia 46 neoadjuvant therapy 46 seroconverted 46 adjuvant therapy 46 squamous cell 46 gemcitabine Gemzar ® 46 Hodgkin lymphomas 46 observational cohort 46 aged ≥ 46 lipid lowering medications 46 investigational monoclonal antibody 46 eosinophilic asthma 46 Tarceva erlotinib 46 hepatocellular carcinoma HCC 46 combined MD Ph.D 46 Idiopathic Pulmonary Fibrosis 46 prostate cancer mCRPC 46 SCCHN 46 taxane 46 evaluable subjects 46 MyVax R 46 carboplatin 46 Erlotinib 46 multiple myeloma MM 46 fludarabine 46 SUTENT 46 chemoradiation 46 lorvotuzumab mertansine 46 randomized Phase III 46 pancreatic neuroendocrine tumors 46 DAPT Study 46 MALT lymphoma 46 aflibercept 46 pancreas transplants 46 BS cum laude 46 follicular NHL 46 distant metastasis 46 infantile onset 46 HCV infected 46 BAY #-# 46 serous ovarian cancer 46 ZADAXIN ® 45 EGFR mutations 45 transthyretin amyloidosis 45 HuMax EGFr 45 Proxinium TM 45 PDX pralatrexate 45 nodular BCC 45 Glioblastoma multiforme 45 IMGN# 45 chronic HCV 45 cancerous enlargement 45 Dual eligibles 45 amrubicin 45 gastroesophageal junction 45 acute myelogenous leukemia AML 45 colorectal carcinoma 45 Perifosine 45 huC# DM4 45 tyrosine kinase inhibitor 45 ISEL 45 GISTs 45 Vectibix 45 Toxicities 45 vinorelbine 45 vandetanib 45 multicenter randomized controlled 45 BRAF V# mutation 45 thymoma 45 anti leukemic 45 metastatic breast cancer 45 Tavocept 45 lung metastases 45 metastatic NSCLC 45 WIA eligibility 45 B CLL 45 prostate cancer PCa 45 Cloretazine R VNP#M 45 multicentre prospective 45 standard chemotherapy regimens 45 NovoTTF 45 TORISEL 45 INCB# [001] 45 chronic lymphocytic leukemia CLL 45 VICTOR E1 45 Halaven 45 Taxotere docetaxel 45 Nonresident undergraduates 45 prostate cancer CaP 45 invasive lobular carcinoma 45 anti angiogenic therapy 45 glufosfamide 45 rituximab Rituxan 45 tyrosine kinase inhibitors 45 Gorlin syndrome 45 daily subcutaneous injections 45 evaluable 45 grade glioma 45 IMC A# 45 LEP ETU 45 EDUCATION BS 45 undergone hysterectomies 45 dasatinib 45 lung ovarian 45 5 fluorouracil 45 liver metastasis 45 follicular lymphoma 45 lymph node metastases 45 chronic myelogenous leukemia CML 45 bevacizumab Avastin 44 Sorafenib 44 multicenter Phase II 44 Carfilzomib 44 EGFR mutation 44 Theratope 44 Phase III HEAT 44 EDUCATION Graduated 44 Albuferon Phase 44 temozolomide 44 Radiation Therapy SIRT 44 cetuximab 44 Lapatinib 44 topotecan 44 relapsing remitting 44 Exherin TM 44 FEHB Program 44 metastatic ovarian cancer 44 paraganglioma 44 dosing cohorts 44 dose cohorts 44 figitumumab 44 ADVEXIN therapy 44 fluorouracil 44 CTCL 44 EGFR inhibitors 44 Satraplatin 44 sodium thiosulfate STS 44 TELINTRA 44 NLSY 44 Anthropology Sociology 44 Telcyta 44 Fund Distribution Reinvestment 44 liver metastases 44 lymph node involvement 44 squamous 44 MSEd 44 ZYBRESTAT 44 KRAS mutation 44 pazopanib 44 microsphere therapy 44 chemoresistant 44 inhaled tobramycin 44 urothelial bladder cancer 44 pomalidomide 44 CoFactor 44 CINTREDEKIN BESUDOTOX 44 Carcinoma 44 EGFR tyrosine kinase inhibitors 44 adenocarcinoma 44 GLP toxicology studies 44 Clolar 44 colorectal cancer CRC 44 Economically disadvantaged students 44 Sutent sunitinib 44 myelodysplastic syndrome MDS 44 vascular disrupting agent 43 laptops parceled 43 Roughly 43 panobinostat 43 prescribed statin 43 Docetaxel 43 Ayumu mom 43 adjuvant chemotherapy 43 Pixantrone 43 vemurafenib 43 hematological malignancies 43 RBRC rechargeable battery 43 Years Programme MYP 43 L BLP# 43 invasive bladder 43 leukaemias 43 randomized #:# 43 cell carcinoma 43 Grab pencil because 43 grade gliomas 43 renal tumors 43 idiopathic pulmonary fibrosis IPF 43 endometrial cancers 43 AQ4N 43 recurrent ovarian cancer 43 capecitabine 43 ASA# 43 dissertation fellowships 43 apaziquone 43 DLBCL 43 TheraSphere 43 anthracyclines 43 lupus nephritis 43 EOquin 43 darapladib 43 GRN#L 43 abiraterone 43 oncological indications 43 Alimta pemetrexed 43 ongoing Phase 1b 43 gradu ated 43 prescribed anti psychotics 43 Phase 1b 43 chemotherapy regimens 43 valopicitabine 43 myelodysplastic syndromes 43 Phase Ib 43 hepatocellular carcinoma 43 bone metastasis 43 Li Fraumeni Syndrome 43 erlotinib 43 tanespimycin 43 myelodysplastic syndromes MDS 43 BLP# Liposome Vaccine 43 malignant pheochromocytoma 43 chemotherapy regimen 43 PARP inhibitor 43 Nimotuzumab 43 sunitinib 43 SCH # 43 entinostat 43 VIDAZA 43 metastatic melanoma 43 pegylated interferon 43 CA4P 43 TREANDA 43 HCV infections 43 proliferative diabetic retinopathy 43 curable cancers 43 talactoferrin 43 ABRAXANE therapy 43 histone deacetylase inhibitor 42 depsipeptide 42 Donated Dental Services 42 Folotyn 42 cangrelor 42 Glioblastoma 42 pheochromocytoma 42 tesmilifene 42 eribulin 42 paclitaxel 42 Phase Ib clinical 42 lung prostate 42 ballet pointe tap 42 rectal cancers 42 neck squamous cell 42 soft tissue sarcoma 42 awaiting kidney transplants 42 National Merit Finalists 42 RG# [001] 42 oropharyngeal cancer 42 Avastin bevacizumab 42 BEXXAR 42 HER2 positive breast cancer 42 dually eligible 42 Cloretazine R 42 carcinoid 42 dirucotide 42 neuroendocrine tumors 42 MEK inhibitors 42 ductal adenocarcinoma 42 renal carcinoma 42 palifosfamide 42 IGNOU launches 42 trastuzumab 42 retrospective cohort 42 Uricase PEG 42 relapsing remitting multiple sclerosis 42 hematologic malignancies 42 FOLOTYN 42 chronic hepatitis C 42 ganetespib 42 multicentre randomized double 42 Phase 2b study 42 systemic lupus erythematosus SLE 42 pancreatic cancers 42 ticagrelor 42 metastatic 42 cell carcinomas 42 afatinib 42 malignant lymphoma 42 GvHD 41 Zolinza 41 Cum laude 41 GIST 41 Phenoptin 41 hematologic disorders 41 cintredekin besudotox 41 baby boomers waved placards 41 bevacizumab 41 Targretin 41 dose escalation study 41 vinflunine 41 prescribed antipsychotics 41 XYOTAX 41 affiliate SISM Research 41 lung adenocarcinomas 41 HCV infection 41 anticancer compound 41 heterozygous FH 41 Phase 2b clinical 41 cisplatin 41 decitabine 41 prelicensure 41 PEP# [003] 41 economically disadvantaged subgroup 41 Meningitis vaccinations 41 Nexavar 41 monotherapy 41 registrational 41 sapacitabine 41 glioblastoma 41 malignant growths 41 Tarceva 41 ASVAB exam between 41 MDV# 41 Amigal 41 GVAX 41 Bridgton Academy prep 41 pleural mesothelioma 41 metastatic cancer 41 solid tumors 41 premalignant lesions 41 breast carcinoma 41 label dose escalation 41 leiomyosarcoma 41 Commended Performance 41 OXi# 41 zalutumumab 41 antitumor effect 41 Xyotax 41 metastatic disease 41 IIIB NSCLC 41 Raloxifene Evaluation MORE 41 astrocytoma 41 TG# [001] 41 acute myeloid leukemia AML 41 tesetaxel 41 OPAXIO 41 bortezomib 40 gastrointestinal cancers 40 statewide voluntary prekindergarten 40 tumor subtypes 40 Underrepresented minority 40 Xcytrin 40 metastatic prostate cancer 40 federally subsidized lunches 40 EpCAM 40 dietary questionnaires 40 prescribed statins 40 esophageal cancers 40 Hodgkin lymphoma NHL 40 hematological cancers 40 chronic myeloid leukemia CML 40 malignancies 40 cell lymphoma DLBCL 40 DMARD 40 panitumumab 40 thymalfasin 40 Alimta 40 chemotherapeutic agent 40 gastric carcinoma 40 Krishna Rajaram 40 T DM1 40 LSC Tomball 40 AARP MedicareRx Saver 40 satraplatin 40 PXD# 40 CACREP accredited 40 Azedra 40 Phase 2b trial